Efficacy of Text-messaging on Activity Limitation in People With Chronic Low Back (NCT06903091) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Efficacy of Text-messaging on Activity Limitation in People With Chronic Low Back
France100 participantsStarted 2026-06-01
Plain-language summary
The main aim of this study was to evaluate the medium-term efficacy of an intervention involving personalized, automated text messaging (SMS), following face-to-face rehabilitation sessions, on activity limitation in people with chronic low back pain. We hypothesize that personalized SMS follow-up, following face-to-face rehabilitation sessions, could reduce activity limitation in people with chronic low back pain. Prospective multicenter randomized controlled trial.
Participants in both groups, experimental and comparator will have 4 face-to-face multidisciplinary rehabilitation sessions.
Participants in the 2 groups will have a face-to-face medical-kinesthetic clinical consultation at M3.
Participants in the experimental group will be monitored by personalized SMS messages over 6 months.
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* People with chronic low back pain (common low back pain, duration of low back pain \> 3 months)
* People who own a cell phone and have mastered the basics of using it (consulting and sending sms).
* Person with a moderate to high self-efficacy for exercise score (SEE score ≥ 31/90).
* Patient having signed the study participation consent form. Patient affiliated to a social security scheme or entitled beneficiary
Exclusion Criteria:
* Any other pathology affecting postural stability or voluntary active mobility
* Contraindication to exercise
* Lumbar spine surgery in the 12 months prior to inclusion in the study
* Inability to write, speak or read French
* Psychiatric and/or behavioral disorders
* Current pregnancy (declarative) No inclusion of persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code (e.g. minors, protected adults, etc.).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.